Compare Abeona Therapeutics Inc (ABEO) vs Global X Uranium ETF (URA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Global X Uranium ETF — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Global X Uranium ETF trades at $41.51. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | URA | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $61.81 |
52-Week Low | $4.17 | $36.45 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
URA trades at $43.88, up 1.5% today, with a bearish technical signal driven by moving averages. The ETF's fundamentals are not detailed in standard ratios, but it focuses on uranium and nuclear energy companies. Recent news highlights strong thematic tailwinds from AI-driven power demand and government support for nuclear energy, positioning URA at the intersection of energy security and technology infrastructure growth.
Outlook is supported by structural demand from AI data centers and policy shifts, but risks include high expense ratios versus peers and concentrated exposure to uranium price volatility. Investor sentiment is cautiously optimistic given the nuclear renaissance narrative, though technical indicators suggest near-term consolidation near key support at $43.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
